Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.
Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA, de Wit R, van den Bergh ACM, Coenen JLLM, Beerlage HP, Hendriks MP, Bos MMEM, van den Berg P, van de Wouw AJ, Spermon R, Boerma MO, Geenen MM, Tick LW, Polee MB, Bloemendal HJ, Cordia I, Peters FPJ, de Vos AI, van den Bosch J, van den Eertwegh AJM, Gerritsen WR. Westgeest HM, et al. Among authors: coenen jllm. Eur Urol Focus. 2018 Sep;4(5):694-701. doi: 10.1016/j.euf.2016.09.008. Epub 2016 Oct 13. Eur Urol Focus. 2018. PMID: 28753794 Clinical Trial.
Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands.
Kuppen MCP, Westgeest HM, van den Eertwegh AJM, Coenen JLLM, van Moorselaar RJA, van den Berg P, Geenen MM, Mehra N, Hendriks MP, Lampe MI, van de Luijtgaarden ACM, Peters FPJ, Roeleveld TA, Smilde TJ, de Wit R, van Oort IM, Gerritsen WR, Uyl-de Groot CA. Kuppen MCP, et al. Among authors: coenen jllm. Clin Genitourin Cancer. 2020 Jun;18(3):e233-e253. doi: 10.1016/j.clgc.2019.11.015. Epub 2019 Dec 5. Clin Genitourin Cancer. 2020. PMID: 31883940
Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry.
Notohardjo JCL, Kuppen MCP, Westgeest HM, van Moorselaar RJA, Mehra N, Coenen JLLM, van Oort IM, de Vos AI, Vervenne WL, van den Bergh ACM, Aben KKH, Somford DM, Bergman AM, Uyl-de Groot CA, Gerritsen WR, van den Eertwegh AJM. Notohardjo JCL, et al. Among authors: coenen jllm. Eur Urol Focus. 2021 Jul;7(4):788-796. doi: 10.1016/j.euf.2020.03.009. Epub 2020 Apr 30. Eur Urol Focus. 2021. PMID: 32362484
CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H. Wissing MD, et al. Int J Cancer. 2015 Mar 15;136(6):E760-72. doi: 10.1002/ijc.29231. Epub 2014 Oct 3. Int J Cancer. 2015. PMID: 25242736
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Badrising SK, van der Noort V, Hamberg P, Coenen JL, Aarts MJ, van Oort IM, van den Eertwegh AJ, Los M, van den Berg HP, Gelderblom H, Vrijaldenhoven S, Kerver ED, van Voorthuizen T, de Jong IJ, Haanen JB, Bergman AM; Dutch Uro-Oncology Study Group (DUOS). Badrising SK, et al. Oncology. 2016;91(5):267-273. doi: 10.1159/000448219. Epub 2016 Aug 20. Oncology. 2016. PMID: 27544669
Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.
Badrising SK, van der Noort V, van den Eertwegh AJ, Hamberg P, van Oort IM, van den Berg HP, Los M, Aarts MJ, Coenen JL, Gelderblom H, de Jong IJ, Kerver ED, Vrijaldenhoven S, van Voorthuizen T, Warmerdam F, Haanen JB, Bergman AM; Dutch Uro-Oncology Studygroup. Badrising SK, et al. Prostate. 2016 Jan;76(1):32-40. doi: 10.1002/pros.23094. Epub 2015 Sep 22. Prostate. 2016. PMID: 26390914
Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223.
Badrising SK, Louhanepessy RD, van der Noort V, Kieffer J, Coenen JLLM, Hamberg P, Beeker A, Wagenaar N, Lam M, Celik F, Loosveld OJL, Oostdijk A, Zuetenhorst H, de Feijter JM, Dezentjé VO, Ras-van Spijk S, Vegt E, Haanen JB, van de Poll-Franse LV, Zwart W, Bergman AM. Badrising SK, et al. Among authors: coenen jllm. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):248-255. doi: 10.1038/s41391-021-00412-6. Epub 2021 Aug 26. Prostate Cancer Prostatic Dis. 2022. PMID: 34446849 Free PMC article.
A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
Badrising SK, Louhanepessy RD, van der Noort V, Coenen JLLM, Hamberg P, Beeker A, Wagenaar N, Lam MGEH, Celik F, Loosveld OJL, Oostdijk A, Zuetenhorst H, Haanen JB, Vegt E, Zwart W, Bergman AM; ROTOR investigators and the Dutch Uro-Oncology Study group (DUOS15101). Badrising SK, et al. Among authors: coenen jllm. Int J Cancer. 2020 Aug 15;147(4):1143-1151. doi: 10.1002/ijc.32851. Epub 2020 Jan 21. Int J Cancer. 2020. PMID: 31875956 Free PMC article.
31 results